Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases

2014 ◽  
Vol 30 (2) ◽  
pp. 320-321 ◽  
Author(s):  
C. Longo ◽  
L. Neri ◽  
G. Argenziano ◽  
S. Calvieri ◽  
P.G. Calzavara-Pinton ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin

scholarly journals Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting

10.36469/9879 ◽  
2014 ◽  
Vol 2 (1) ◽  
pp. 1-14
Author(s):  
Michael Willis ◽  
Sandra Erntoft ◽  
Sofie Persson ◽  
Jenny M. Norlin ◽  
Ulf Persson
Keyword(s):  
Willingness To Pay ◽  
Actinic Keratosis ◽  
Topical Treatment ◽  
Treatment Duration ◽  
The United States ◽  
Tolerability Profile ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin ◽  
Topical Treatments

Background: Currently available topical treatments for actinic keratosis (AK) adversely affect patients’ quality of life because of long treatment durations and long-lasting local skin reactions (LSRs), which may result in poor treatment adherence and patient outcomes. Ingenol mebutate gel, a recently introduced treatment for AK, is administered for 2 or 3 days, and LSR’s are predicable in onset and duration. Objectives: The objective of the study was to estimate the value of ingenol mebutate gel’s shorter treatment duration and tolerability profile to potential patients, versus existing topical treatments (imiquimod 3.75%, imiquimod 5% and diclofenac 3%) in the United States. Methods: The open-ended Contingent Valuation (CV) approach was used to estimate incremental willingness-to-pay (WTP) for ingenol mebutate gel rather than treatment with imiquimod 5%, imiquimod 3.75% and diclofenac 3%. Profiles for each therapy differed in regards to treatment duration, time-to-LSR resolution, and price. Subjects were asked to state their maximum out-of-pocket WTP to receive ingenol mebutate gel instead of each of the three alternatives. Results: 103 subjects provided usable answers. Between 48% and 63% of subjects were willing to pay extra to gain access to treatment with the ingenol mebutate gel profile instead of the comparators, and the mean incremental WTP ranged from $475 to $518. Subjects with experience of topical treatment stated higher WTP for accessing ingenol mebutate gel. Subjects whose most bothersome AK area was the full scalp or forehead also claimed higher WTP for ingenol mebutate gel. Conclusions: Patients diagnosed with AK indicated an unmet need for fast-acting topical treatment with shorter LSR resolution time.

scholarly journals Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

2020 ◽  
Vol 4 (5) ◽  
pp. s65
Author(s):  
Scott Freeman ◽  
Miriam Bettencourt ◽  
Meg Corliss ◽  
Nikeshia Dunkelly-Allen ◽  
Karen A Veverka
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin

Abstract not available.

scholarly journals Local skin reactions following the administration of topical ingenol mebutate for actinic keratosis

2017 ◽  
Vol 23 (9) ◽  
Author(s):  
Alberto Conde-Taboada ◽  
Bárbara Mercado ◽  
Beatriz Aranegui ◽  
Elena González-Guerra ◽  
Eduardo López-Bran
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin

scholarly journals Severe local skin reaction after the application of ingenol mebutate gel treated by photodynamic therapy: A case report

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Luca Negosanti ◽  
Rossella Sgarzani ◽  
Matteo Santoli ◽  
Massimino Negosanti ◽  
Nicoletta Banzola ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Actinic Keratosis ◽  
Aminolevulinic Acid ◽  
Severe Side Effect ◽  
Severe Reaction ◽  
Ingenol Mebutate ◽  
Local Skin ◽  
Local Skin Reaction ◽  
Patient Reported ◽  
Local Reactions

<p>Ingenol mebutate (IM) was recently introduced for the treatment of actinic keratosis (AK). It is considered a safe and effective treatment in spite of local reactions frequently reported. These reactions may consist of erythema, flaking, crusting, swelling, vesicles and erosions, and would usually spontaneously recede within 20–30 days. We reported a case of a patient affected by multiple actinic keratosis of the scalp treated with IM. The patient reported a severe reaction that was not solved in two months. We decided to treat the reaction with photodynamic therapy and aminolevulinic acid. This treatment was demonstrated to be effective in solving this severe side effect.</p>

Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial

2017 ◽  
Vol 1 (3) ◽  
pp. 128-142 ◽  
Author(s):  
Daniel Siegel ◽  
Emil Tanghetti ◽  
Neil Brody ◽  
Michael Freeman ◽  
Torsten Skov ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Controlled Trial ◽  
Background Field ◽  
Dose Finding ◽  
Application Site ◽  
Ingenol Mebutate ◽  
Double Blind ◽  
Local Skin ◽  
Complete Clearance ◽  
Pathological Review

Background: Field treatment of actinic keratosis (AK) can eradicate clinical and sub-clinical lesions; treatments for extended skin areas are required.Methods: This randomized, double-blind, vehicle-controlled trial (NCT01998984) evaluated ingenol mebutate (IngMeb) 0.06% gel for AK treatment over extended areas. Adults with 5–20 AK lesions within a 250 cm2 area of skin on the trunk (except chest) or extremities were randomized to: 2 days vehicle, 2 days IngMeb (2D, n=55); 1 day vehicle, 3 days IngMeb (3D, n=59); 4 days IngMeb (4D, n=49); or 4 days vehicle (n=61). Week 8 primary endpoint was complete clearance of AK lesions; secondary endpoints included reduction in AK count and partial clearance. Adverse events (AEs) were recorded and local skin responses (LSRs) assessed. A hierarchical testing scheme, starting with 3D versus vehicle, was used.Results: In total, 224 patients were randomized. At Week 8, for 2D, 3D, 4D, and vehicle groups, complete clearance rates were 12.7%, 5.1%, 26.8%, and 0.0% (3D vs. vehicle, p=0.18); reductions in AK count were 63.0%, 66.8%, 73.6%, and 11.9%, respectively. LSR scores peaked at Day 5 (3D and 4D), and Days 5 and 10 (2D). Application-site pain and pruritus were common AEs. Of 15 neoplasm AEs, 14 were designated keratoacanthomas and one squamous cell carcinoma by central pathological review. The 4D group was closed based on pre-defined criteria.Conclusions: All three regimens were effective at reducing AK count on trunk/extremities. The 4D treatment was not well tolerated. Complete clearance was not significantly different to vehicle.

Sign in / Sign up

Export Citation Format

Share Document